Annals of medicine and surgery (2012) · 2026
Eosinophilic gastroenteritis in a 45-year-old female with epigastric abdominal pain: a rare case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mousa Ayham, Daas Laila, Hababeh Mohamad Nour, Alhofari Betoul, Thalaj Loujain, Al Erksoussi Leen, Abo Shukr Jana, Salman Leen, Sleiay Bilal, Sleiay Mouhammed
Аннотация
INTRODUCTION AND IMPORTANCE: Eosinophilic gastroenteritis (EGE) is a rare condition characterized by eosinophilic infiltration of the gastrointestinal tract, commonly presenting with abdominal pain, diarrhea, and peripheral eosinophilia. Corticosteroids are traditionally considered the mainstay of treatment.
CASE PRESENTATION: A 45-year-old female presented with epigastric abdominal pain. Laboratory tests revealed marked peripheral eosinophilia, and upper endoscopy with biopsies confirmed mucosal-type EGE. The patient declined corticosteroid therapy and was commenced on montelukast 10 mg daily. She achieved complete symptom resolution within 2 weeks and maintained remission over a 12-month follow-up.
CLINICAL DISCUSSION: Corticosteroids remain the standard treatment for EGE, effectively reducing eosinophil counts and inflammatory mediators. In patients unable or unwilling to receive steroids, leukotriene receptor antagonists, such as montelukast, offer a viable alternative, demonstrating rapid symptom relief and potential for sustained remission.
CONCLUSION: Physicians should recognize EGE and its therapeutic complexities. Montelukast may serve as an effective corticosteroid-sparing strategy, enabling early symptom resolution and long-term remission.
CASE PRESENTATION: A 45-year-old female presented with epigastric abdominal pain. Laboratory tests revealed marked peripheral eosinophilia, and upper endoscopy with biopsies confirmed mucosal-type EGE. The patient declined corticosteroid therapy and was commenced on montelukast 10 mg daily. She achieved complete symptom resolution within 2 weeks and maintained remission over a 12-month follow-up.
CLINICAL DISCUSSION: Corticosteroids remain the standard treatment for EGE, effectively reducing eosinophil counts and inflammatory mediators. In patients unable or unwilling to receive steroids, leukotriene receptor antagonists, such as montelukast, offer a viable alternative, demonstrating rapid symptom relief and potential for sustained remission.
CONCLUSION: Physicians should recognize EGE and its therapeutic complexities. Montelukast may serve as an effective corticosteroid-sparing strategy, enabling early symptom resolution and long-term remission.